Interstitial Cystitis Clinical Trial
Official title:
Mindfulness-Based Therapy for Interstitial Cystitis/Bladder Pain Syndrome
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a poorly understood disease with unreliable treatments. Although it is not known what causes it for certain, we do know that life stressors may make the disease worse or cause flares. Mindfulness Based Stress Reduction (MBSR) is an 8 week class focused on meditation and other techniques that the investigators think may be helpful to people with IC/BPS. This trial will assign participants to an MBSR class or usual care for their IC/BPS to see if the MBSR class would be helpful for their disease.
BACKGROUND/SCIENTIFIC RATIONALE Interstitial cystitis/bladder pain syndrome (IC/BPS) is
associated with significant morbidity and poorly understood underlying pathophysiology.
IC/BPS comprises a symptom complex defined by the American Urological Association (AUA) as
"An unpleasant sensation (pain, pressure, discomfort) perceived to be related to the urinary
bladder, associated with lower urinary tract symptoms of more than six weeks duration, in the
absence of infection or other identifiable causes"(1). Up to 11% of women are affected by
IC/BPS (2), and the disorder may be significantly underdiagnosed (3). A 2008 study (4)
indicated that 43% of patients with IC/BPS require multimodal therapy with an average of 7-12
yearly clinic visits at a cost of $9,000/patient. Twenty percent of women report wage losses
of >$4000 per year (5). Current theories for the cause of IC/BPS include infectious agents, a
defective uroepithelium permeable to toxic substances, structural abnormalities, neurogenic
inflammation, increased neurologic sensitivity, or an allergic response involving increased
numbers of bladder mast cells (6). Despite these theories, reliable treatments remain
elusive. Most IC/BPS treatments target one of these proposed mechanisms, involve trial and
error of several therapies (1), and often utilize multiple modalities (7). Treatment success
ranges from 47-93% for intravesical instillation to 21-64% for oral therapies, with
discontinuation rates up to 80% due to intolerable side effects (1). Efficacious treatments
for IC/BPS that apply to a greater proportion of patients with limited side effects are
urgently needed.
Mindfulness Based Stress Reduction (MBSR), a Complementary Alternative Medicine (CAM)-based
therapy, potentially fulfills this need. The Interstitial Cystitis Association (ICA), a
patient-led organization, sponsored a survey of 2100 IC/BPS patients. They reported that 84%
had tried CAM therapy and 55% of those surveyed reported that their physicians had
recommended CAM (8). According to a 2007 National Health Interview survey (9), CAM is used by
38% of adults in the United States. MBSR has been successfully employed to treat chronic pain
syndromes and has been used in disorders such as multiple chemical sensitivity, chronic
fatigue syndrome, fibromyalgia (10), and irritable bowel syndrome (IBS) (11). These disorders
may coexist in patients with IC/BPS (6). In IC/BPS, increases in stress are positively
correlated with increased pain (12); and one study reported that up to 80% of IC/BPS patients
found stress reduction decreased their symptoms (8). MBSR was found to be efficacious in the
treatment of urgency urinary incontinence, a urinary disorder closely related to IC/BPS (13,
14). While MBSR has shown therapeutic promise in conditions that are similar to or coexist
with IC/BPS, and has been rated as helpful by patients suffering from IC/BPS, rigorous
randomized clinical trials investigating the efficacy of this intervention are lacking (8).
OBJECTIVES/AIMS/HYPOTHESES Ultimately, the investigators long-term goal is to provide a
much-needed treatment for IC/BPS using patient-centered therapy such as MBSR. The objective
of this research is to conduct a pilot RCT to explore whether MBSR is acceptable to patients
and results in improved symptoms when added to IC/BPS 1st and 2nd-line treatments as
recommended in the American Urological Association guidelines (see Table 1). The
investigators hypothesize that an 8-week MBSR class will be acceptable to IC/BPS patients and
that MBSR used in conjunction with traditional 1st and 2nd line therapies will improve
symptoms compared to IC/BPS patients using traditional 1st and 2nd line therapies alone. If
this pilot study demonstrates effectiveness and acceptance of MBSR, it would provide data to
justify a larger randomized controlled trial. If the investigators' hypothesis is supported
with this exploratory study, MBSR, an understudied and potentially underutilized therapy,
will expand treatment options for IC/BPS patients. The investigators' aims in pursuit of this
goal are; Aim #1: To determine whether the addition of MBSR to 1st and 2nd line therapies as
recommended by AUA guidelines improves IC/BPS symptoms as measured by the primary outcome the
Global Response Assessment (GRA), as well as the O'Leary-Sant Symptom and Problem Index
(OSPI), and Visual Analog (VAS) pain scale. Hypothesis: The investigators hypothesize that
MBSR will be an effective treatment for IC/BPS as measured by the validated GRA, O'Leary-Sant
and VAS pain scales.
Aim #2: To evaluate whether participation in a structured MBSR class will improve quality of
life, sexual function and overall self-efficacy in patients with IC/BPS, based on changes in
the Short Form Health Survey (SF-12), Female Sexual Function Index (FSFI), and the Pain
Self-Efficacy Scale (SES). Hypothesis: The investigators' hypothesize that MBSR will improve
quality of life, sexual function and impressions of self-efficacy as measured by these
validated scales
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04313972 -
IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone
|
Phase 4 | |
Completed |
NCT03282318 -
A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis
|
Phase 2 | |
Completed |
NCT03463499 -
The Efficacy and Safety of Intravesical Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients
|
N/A | |
Completed |
NCT02898220 -
Trans-MAPP II Study of Urologic Chronic Pelvin Pain
|
||
Terminated |
NCT02591199 -
Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
|
Phase 2 | |
Completed |
NCT02247557 -
Intravesical Instillation of Liposome Encapsulated Botulinum Toxin A (Lipotoxin) in Treatment of Interstitial Cystitis
|
Phase 2 | |
Active, not recruiting |
NCT01731470 -
Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)
|
N/A | |
Completed |
NCT01197261 -
OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS)
|
Phase 2 | |
Completed |
NCT00971568 -
Urinary Biomarkers Characteristic to Interstitial Cystitis
|
N/A | |
Completed |
NCT00527917 -
A Pilot Clinical Investigation of the Efficacy and Safety of Uracyst® Versus Placebo in Patients With Interstitial Cystitis/Painful Bladder Syndrome.
|
Phase 2 | |
Completed |
NCT00150488 -
URACYST® For the Treatment of GAG Deficient Interstitial Cystitis
|
N/A | |
Recruiting |
NCT00094874 -
Acupuncture for the Treatment of Interstitial Cystitis (IC) Symptoms
|
Phase 3 | |
Terminated |
NCT00086684 -
Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis
|
Phase 4 | |
Recruiting |
NCT04845217 -
Peppermint Oil for the Treatment of Interstitial Cystitis / Bladder Pain Syndrome
|
Phase 1/Phase 2 | |
Completed |
NCT04401176 -
Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome
|
Phase 2 | |
Recruiting |
NCT05147779 -
Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Peyronie's Disease, ED, and Interstitial Cystitis
|
Phase 1 | |
Suspended |
NCT04450316 -
Low-dose Naltrexone for Bladder Pain Syndrome
|
Phase 2 | |
Completed |
NCT04010513 -
Hypnosis for Bladder Pain Syndrome
|
N/A | |
Completed |
NCT05179460 -
A Study of Pentosan Polysulfate Sodium and the Development of Pigmentary Maculopathy and Pigmentary Retinopathy
|
||
Completed |
NCT02232282 -
Acupuncture for Female IC/PBSyndrome and Its Effect on the Urinary Microbiome: A Randomized Controlled Trial
|
N/A |